News >

Regorafenib HCC Benefits Consistent in Additional Analyses

Silas Inman @silasinman
Published: Monday, Apr 30, 2018

Richard S. Finn, MD

Richard S. Finn, MD
Second-line regorafenib (Stivarga) continued to show antitumor activity regardless of prior dose or time to progression (TTP) on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma (HCC), according to additional analyses from the phase III RESORCE trial published in the Journal of Hepatology.1

Regorafenib was approved by the FDA in April 2017 for the treatment patients with hepatocellular carcinoma (HCC) who have previously received sorafenib, based on findings from the RESORCE trial. The agent is also approved for the treatment of patients with metastatic colorectal cancer and advanced gastrointestinal stromal tumors.

References

  1. Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial [published online April 25, 2018]. J Hepatol. 2018.
  2. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x